Changes in Care for Acute Pulmonary Embolism Through A Multidisciplinary Pulmonary Embolism Response Team - 05/11/20
, Sebastian E. Beyer, MD, MPH b, Tyler Mehegan, MD b, Andrew Dicks, MD b, Abby Pribish, MD b, Andrew Locke, MD a, Anuradha Godishala, MD a, Kevin Soriano, MD b, Jaya Kanduri, MD b, Kelsey Sack, MD, PhD b, Inbar Raber, MD b, Cara Wiest, MD b, Isabel Balachandran, MD b, Mason Marcus, MD b, Louis Chu, MD c, Margaret M. Hayes, MD d, Jeff L. Weinstein, MD e, Kenneth A. Bauer, MD f, Eric A. Secemsky, MD b, Duane S. Pinto, MD, MPH bAbstract |
Background |
Optimal management of acute pulmonary embolism requires expertise offered by multiple subspecialties. As such, pulmonary embolism response teams (PERTs) have increased in prevalence, but the institutional consequences of a PERT are unclear.
Methods |
We compared all patients that presented to our institution with an acute pulmonary embolism in the 3 years prior to and 3 years after the formation of our PERT. The primary outcome was in-hospital pulmonary embolism-related mortality before and after the formation of the PERT. Sub-analyses were performed among patients with elevated-risk pulmonary embolism.
Results |
Between August 2012 and August 2018, 2042 patients were hospitalized at our institution with acute pulmonary embolism, 884 (41.3%) pre-PERT implementation and 1158 (56.7%) post-PERT implementation, of which 165 (14.2%) were evaluated by the PERT. There was no difference in pulmonary embolism-related mortality between the two time periods (2.6% pre-PERT implementation vs 2.9% post-PERT implementation, P = .89). There was increased risk stratification assessment by measurement of cardiac biomarkers and echocardiograms post-PERT implementation. Overall utilization of advanced therapy was similar between groups (5.4% pre-PERT implementation vs 5.4% post-PERT implementation, P = 1.0), with decreased use of systemic thrombolysis (3.8% pre-PERT implementation vs 2.1% post-PERT implementation, P = 0.02) and increased catheter-directed therapy (1.3% pre-PERT implementation vs 3.3% post-PERT implementation, P = 0.05) post-PERT implementation. Inferior vena cava filter use decreased after PERT implementation (10.7% pre-PERT implementation vs 6.9% post-PERT implementation, P = 0.002). Findings were similar when analyzing elevated-risk patients.
Conclusion |
Pulmonary embolism response teams may increase risk stratification assessment and alter application of advanced therapies, but a mortality benefit was not identified.
Le texte complet de cet article est disponible en PDF.Keywords : Catheter-directed thrombolysis, Inferior vena cava filters, Pulmonary embolism, Response teams, Systemic thrombolysis
Plan
| Funding: None. |
|
| Conflict of Interest: DSP is a consultant for Abbott Vascular, Abiomed, Boston Scientific, Medtronic, NuPulseCV, and Teleflex. KAB has served as a consultant for Bristol Myers Squibb. EAS has received research grants to BIDMC: AstraZeneca, BD Bard, Boston Scientific, Cook Medical, CSI, Medtronic, Philips, and the University of California, San Francisco; is a consultant for BD Bard, CSI, Janssen, Medtronic, and Philips; and is on the speaking bureau for BD Bard, Cook Medical, and Medtronic. The remaining authors have no relevant disclosures. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 133 - N° 11
P. 1313 - novembre 2020 Retour au numéro
Article précédent
- Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI
- Raffaele De Caterina, Antonio Procopio, José-Luis Lopez Sendon, Dimitar Raev, Shamir R. Mehta, Grzegorz Opolski, Jonas Oldgren, Philippe Gabriel Steg, Stefan H. Hohnloser, Gregory Y.H. Lip, Takeshi Kimura, Eva Kleine, Jurriën M. ten Berg, Deepak L. Bhatt, Corinna Miede, Matias Nordaby, Christopher P. Cannon, on behalf of the RE-DUAL PCI Steering Committee and Investigators
- A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy
- Madeleine Alder, Aakash Bavishi, Katelyn Zumpf, Jonna Peterson, Neil J. Stone
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?